Podcast

The urologist's role in dispelling men's health myths

Author(s):

Urology Times staff

“I think it's really important to understand the role of prevention and early detection,” says Michael Lutz, MD.

In this episode, Urology Times® Assistant Managing Editor Ben Saylor spoke with Dr. Michael Lutz. He discusses common myths and misconceptions surrounding men’s health and the urologist’s role in dispelling them. Lutz is a partner in the Michigan Institute of Urology and president of the MIU Men’s Health Foundation.

Related Videos
Justin Dubin, MD, answers a question during a video interview
Man talking with a doctor | Image Credit: © RFBSIP - stock.adobe.com
Related Content
Skyler Howell, MD | Credit: X.com
April 28th 2025

AUA 2025: GLP-1 RAs could improve sperm count in overweight men

Patrick Campbell
New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.
Pearls & Perspectives: Martin Kathrins, MD, on MED3000 and learning from failed trials
April 28th 2025

Pearls & Perspectives: Martin Kathrins, MD, on MED3000 and learning from failed trials

Amy M. Pearlman, MD Martin Kathrins, MD
Kathrins discusses the intricacies of leading a clinical trial and why "negative" trials are important to informing care strategies.
Nathan Lawrentschuk, MBBS, PhD | Credit: Epworth Healthcare
April 26th 2025

ADAM, a long-term, injectable male birth control, shows promise at AUA 2025

Patrick Campbell
A groundbreaking male contraceptive shows promising safety results, offering a reversible option for couples seeking effective birth control.
Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS
In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
Label change for testosterone: Implications for urologists, prescribers, and patients
April 9th 2025

Label change for testosterone: Implications for urologists, prescribers, and patients

Hannah Clarke
In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.
Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan
March 31st 2025

Investigational Combination Immunotherapy Treatment for High-Risk, Late-Stage Prostate Cancer Patients Available in Michigan

Michigan Institute of Urology
Michigan Institute of Urology is a clinical trial site for LEGION-100.
© 2025 MJH Life Sciences

All rights reserved.